應用DHPLC技術進行診斷性分析的質量保證體系_第1頁
應用DHPLC技術進行診斷性分析的質量保證體系_第2頁
應用DHPLC技術進行診斷性分析的質量保證體系_第3頁
應用DHPLC技術進行診斷性分析的質量保證體系_第4頁
應用DHPLC技術進行診斷性分析的質量保證體系_第5頁
已閱讀5頁,還剩61頁未讀 繼續(xù)免費閱讀

下載本文檔

版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領

文檔簡介

應用DHPLC技術進行診斷性分析的質量保證體系張澤云美國環(huán)球基因公司中國代表處診斷性分析的要求臨床分子遺傳學分析的復雜性臨床分子檢測結果的一致性和精確性

變性高效液相色譜(DHPLC)作為一種高效和敏感的基因突變檢測技術DHPLC技術質量控制AMERICANCOLLEGEOFMEDICALGENETICS

StandardsandGuidelinesforClinicalGeneticsLaboratories

2005Edition

G:CLINICALMOLECULARGENETICS

TheseStandardsandGuidelinesspecificallyrefertotheuseofmoleculartechniquestoexamineheritableorsomaticchangesinthehumangenome.

G18

DenaturingHighPerformanceLiquidChromatography(dHPLC)

(SectionAddedNovember2003)CMGSBestPracticeGuidelinesUseoftheWAVESysteminDiagnosticService

PreparedandeditedbyJohnHarvey,NationalGeneticsReferenceLaboratory(Wessex),Salisbury,UKandElsSchollen,CentreforHumanGenetics,Leuven,Belgium

lastupdate:12March2004

?Introduction

?Laboratoryprocess

?DHPLCsystem

?Dataquality

?Checking&reporting

guidelines

?References

DHPLCSOPsInstrumentormaintenance

SOPTechnique

GeneralDHPLCSOPWAVE3500,3500HTMethod

Disease-specificSOPsRett,BRCA,HNPCC

Marfan,…Applicationcompany+usersgeneralusers+companyspecificusers

SupplementaryAppendix1

STANDARDOPERATINGPROCEDUREWAVE?SystemOperationandMaintenance

SOP-O&M

WAVE?SystemOperationandMaintenance

ForWAVE?SystemModels3500,3500Aand3500HTWAVE?SystemOperationandMaintenance

AnalysisoftheWAVE?Low&HighRangeMutationStandardsThemaintenanceprocedureDNASep?andDNASep?HTcartridgemaintenance

RoleofMutationstandards:

checkingofcorrectfunctioningoftheWAVE?System,includingovencalibration,cartridgeperformance,buffercompositionandstability,toensurereproducibilityandaccuracyofthechromatographicanalysis.

Mutationstandardsberunwhen:

l

Theroutinepre-run,

l

Weeklyandmonthlymaintenanceprocedure,

l

Afterreplacementofanycomponent,

l

Validationforanewbatch,

l

Asanassaycontrol,atthebeginningandendofeveryrun,preferablyalsoafterevery100injectionsforlongruns.

AnalysisoftheWAVE?Low&HighRangeMutationStandards

NormalrangesofthemutationstandardsThemaintenanceprocedure3.1Filterandflush3.2Pre-runmaintenance3.3Weeklymaintenance3.4Quarterlymaintenance3.5Othermaintenanceoperations3.6Preventativemaintenanceprocedureandsystemvalidation

Filterandflush

Theprincipleoffiltrationinvolvespreventingunwantedcontaminantsfromenteringthesystem.Filtrationappliestotwospecificareas:solventfiltrationandin-linefiltration.Thesystemflushingistoremovemobilephasesaltcomponentsthatcanprecipitateunderstrongsolventconditions.

Pre-runmaintenance1.Buffercheck2.Injectionsystemwashing3.Pressurecheck4.Checktheabsorbanceonthedetector5.Purgethelines

WeeklymaintenanceInlinefilterreplacement

Checkthesyringe

Quarterlymaintenance

CheckUVlamp

UVlampreplacement

Cleaningthesystem(Isopropanolcleaning)

DNASep?andDNASep?HTcartridgemaintenance

1.

Regularmaintenanceschedule

Every96-192injections:Extendedhotwash

Every1000injections:Reversehotwash

DNASep?wash(ifreversehotwashfailstoresolvemutationstandards)2.Short-termcartridgestorage3.Long-Termcartridgestorage4.NewcartridgeinstallationDailyMaintenanceEquilibratethecartridge50%A50%Bfor15minutesRun1-2blanksVerifysystemperformance(pre-analysis)RunastandardRunSamplesVerifysystemperformance(postanalysis)WeeklyMaintenanceAnExtendedActiveCleanWashisrecommendedevery~100injections.(Usuallydoneaftereach96wellplate)OvenSetto:80°CPumpSetto:100%D15-30minutesWASHOvenSetto:56°CPumpSetto:50%A-50%BEQUILIBRATE45-90minutesRunStandardstoVerifySystemPerformance!1000InjectionMaintenanceAReverseHotWashisrecommendedevery~1000injectionsUV/FLDetector

TurnoffthepumpReversethecartridgedirection.Settheovento80°C.Setthepumpto100%D.60-90minutesStoringtheCartridgeFlushthecartridgewith100%DBuffer.RemovethecartridgefromtheWAVESystem.Capthecartridgewithendplugs.Storethecartridgeatroomtemperature.InstallingaNewCartridgeStopthepumpflowandremovetheoldcartridge.Removetheplugsfromthenewcartridge.Installthenewcartridgewiththearrowpointingtowardtherearoftheoven.UV/FLDetectorMakesuretheovenheatsuptoatleast40°C.Setthepumpto100%D@0.500mL/min.Ensurethepressureisstableandgraduallyincreasetheflow(0.9mL/minor1.5mL/min).Flushthecartridgefor15minutes.Setthepumpto50%BufferA,50%BufferBandequilibratefor30minutes.EquilibratingaNewCartridge100%50%50%VerifyNewCartridgePerformanceLow-RangeMutationStandardDNASizingControlStandard

SupplementaryAppendix2STANDARDOPERATINGPROCEDUREDHPLCSOP-DHPLC

DHPLCmutationdetectiononTransgenomicWAVE?System3500Wavemaker?4.1.44&HSM3.0-2.1(build2)Navigator?1.5.4(build19)

PCRrequirementsPrimerdesignTemplatepurityandconcentrationDNAPolymerasesPCRbuffermixPCRplatesPCRqualityandProductmixingPost-PCR,filmuseControlsPrimerDesignUseaprimer-pickingprogramPrimersshouldideallybenocloserthan30-50bpfromtheendofthesequencetobeanalyzedformutationsPrimersshouldbe18-30bpinlengthTheTmdifferencebetweenprimersinapairshouldideallybelessthan2°C.SizeofPCRfragmentTheoptimalsizerangefordetectingmutation/SNPsbyDHPLCwith100%accuracyis150-500bp.Fragments>500bpcanbegeneratedbutsensitivitydecreasedandtimeofelutionincreased.Forfragments<150bp,differenceofmeltingpointbetweenfragmentstoonarrow(thefragmentsmeltovertoonarrowatemperaturerange).QuantityofPCRfragmentThePCRproductshouldbesufficientlyconcentratedthat2μlrunonanagarosegelproducesaclearlyvisibleband(~20ng/μl)Dilutesamples(verylowyields)producepoorqualityresults(poorsignal:noiseratio).Veryhighyieldscanleadtolargeproportionsofmisincorporationsandhenceincreaseddifficultyincallingmutations.Usually3-10μl(~50-200ng)ofunpurifiedPCRproductwouldbeinjectedontothecolumn(peronetemperature).A8μlminimumaliquotofPCRproductshouldbesuppliedinPCRtubesinstripsof8(peronetemperature).SamplePreparationforDHPLCDNAmustbeclean,allcellulardebrisandorganiccompoundsmustberemoved.Saltingoutmethodispreferred.DNAextractedwithsomecommercialsystemsmaybedilutedto10ngtoreduceeffectsofimpuritiestoPCR.DNAoflowqualitywillresultinsub-optimalPCRresults(henceDHPLCprofiles).DNAquality&concentrarionTable1.RecommendedcleaningproceduresforDNAextraction.IsolationMethodRecommendedAdditionalCleaning:OrganicExtraction

(e.g.phenol/chloroform)Chloroform/isoamylback-extractionfollowedbyethanolprecipitationandwashChaotropicSalts

(e.g.guanidiniumisothiocyanate)EthanolprecipitationandwashSpinColumnEthanolprecipitationandwashTable2.RecommendedDNAquantitiesusedforPCR(50μLreaction).TemplateRecommendedQuantityHumangenomicDNA50-200ngPhageDNA1-10pgPlasmidDNA0.1-1.0pgTheImportanceofPolymeraseFidelityforMutationDetectionImportanceofhighfidelityindHPLC500bpWildTypeFragmentRedTrace–OptimasePolymeraseGreenTrace–9:1MixAmplitaqGoldandPfuTurboHeteroduplexduetomisincorporationPolymeraseFidelityComparisonMaximumrecommendedconcentrations

ofacceptablePCRadditivesAcceptableadditives(maximumfinalconcentration)Additiveswherefinalconcentrationmustbe<1%10%

DMSOHighMolecularweightstabilizers:-polyethyleneglycol(PEG)2%

GlycerolDetergentsincludingbutnotlimitedto:TritionX100-NP40Tween20-SDS/SLS1.25to2.5M

BetaineUseofthesecomponentsrequirestheuseof'Activeclean'foreachinjection,andotheradditionalcleaning.Fluorescentlabelswillnotdamagethecolumnbutarenotrecommended.Digoxigenin/biotinlabelledprimershavenotbeentested.UnacceptablePCRcomponents.TemplateDNAextractedorpurifiedinamannernotconsistentwithWAVE’srecommendationGelpurificationcannotbeusedtocleanupsamplesforDHPLC,asthereagentsandresidualagarosedamagethecolumn.Unidentifiedreagent:“proprietary” -“stabilizers”“enhancers” -“additives”AutoclavedWaterMineralOilFormamideProteinaseKBovineserumalbumin(BSA)Loadingdyes(cresolred)(ComponentscausingirreversibleDNASepcartridgedamage)AnalysisofPCRProductsontheWAVESystemRunPCRProductsat50°C(non-denaturingconditions)toverifysize,yieldandpurityRunPCRProductsunderpartially-denaturingconditionstoverifyfidelity.Controls

PCRPositivecontrols

PCRNegativecontrolsInstrumentcontrols:LowandHighRangeMutationstandardsControlsamplesinDHPLCWhereverpossible,aconfirmedwild-typecontrolshouldberun,andcomparedwitheachsample.Amutation(positive)controlshouldbeincluded.Whenamplifyinglargenumbersofsamplesformanydifferentgenefragmentswithalowfrequencymutationpickuprate,itissometimesacceptabletoomitanormalcontrol.InstrumentBuffersCommercialbuffersPreparationof‘In-house’Buffers

Heteroduplexformation

·

Allsamplesmustbeheteroduplexed;·Heteroduplexformation:95oCfor5minandcoolslowly(minimum10s/°C)toroomtemperature.

·Fastercoolingprotocolsusedforheteroduplexformationcanseriouslyimpairheteroduplexing.·

PurificationofPCRproductscanseriouslyimpairheteroduplexformation.

SoftwareWaveMaker?4.1.44

Navigator?

ProjectSet-upSelectionofanalysistemperaturesbasedonmeltprofilesAdjustmentofgradientswithtimeshifts.

ResultsInterpretation

ChromatogramControlsMinimumpeakintensityVisualassessmentofchromatogramsTracespecifity

AssessmentofchromatogramqualityA:ContainsunincorporatednucleotidesandprimerswhichdonotbindtothecolumB:ContainsprimerdimersC:MaybecausedeitherbyTaqerrorsduringPCRorbynon-templateAaddition.D:Themajorityofwildtypesamplesappearasasinglepeak.E:ACNabsorbsat260nm.AnyhighMWcontaminantsappearasspikesonthispeak.Typicalhomozygouswild-typechromatogramACBDERetentiontime(minutes)A260nmInjectionpeakACNwashpeakSamplepeakControlsCheckthemutationstandardsandseeiftheyfulfilthecriteriadescribedinSOP-O&M.Checktheknownsequencevariants(positivecontrols).Iftheydonotpresentanaberrantchromatogramattheoptimalscreeningtemperature,theresultsshouldberejectedandtheanalysisrepeatedIdeallythesignalintensityofDHPLCprofilesshouldbe>2mVatA260.Peaksofintensity>30%oftheaveragepeakintensity.Weakpeaksaremorelikelytoleadtofalse-negative/positiveresults.MinimumpeakintensityIdentificationofsequencevariantsThepresenceofheteroduplexesisoftendetectedasachangeinthenumberofpeaks(maybe2,3or4peakpattern).Twopeakpatternsaccountforthemajorityofmutations.Completeresolutionofthe2heteroduplexesisnotalwaysnecessary.Mutationsmayappearonlyasaslightbroadeningofthesinglepeak,orasasubtlechangetoashoulderonthepeak.AllsamplesidentifiedasheteroduplexesbyDHPLCanalysismustbesequencedinbothdirectionstoconfirmanddeterminethenatureofthesequencechange.Thehomoduplexwild-typepatternistypically1peak,butmaybe2peaks,dependinguponthemeltingprofile.Elutionprofilesthatdifferfromthewild-typeindicatethepresenceofDNAsequencechanges.Butthemutationtypecannotbepredictedfromtheheteroduplexpattern.EachmutationinagivenPCRfragmentispredictedtohaveauniqueheteroduplexpattern(highlyspecificelutionprofile).Thisisusefulforquickgenotypingofunknownsamplesbycomparisonwithpositivecontrolsamples.However,traceprofilesarenotalwaysuniqueforaspecificmutation,i.e.differentDNAvariantscangiveidenticalprofiles.Changesinretentiontimedonotaccuratelypredictthepresenceofasequencechange.TracespecificityDatachecking,reportingandstorage

DatacheckingPositiveresultsFalsepositiveresultsNegativeresultsFalsenegativeresultsSensitivityDetectionofmosaicsArchiving

SupplementaryAppendix3STANDARDOPERATINGPROCEDUREMECP2SOP-MECP2

DHPLCscreeningofMECP2InthecontextofRettSyndromeRettsyndrome

Childhoodneurodevelopmentdisorderwithaprevalenceof1/10.000to1/15.000infemalebirthsMutationsintheMECP2gene,codingforMethylCpGBindingProtein2,aretheprimarycauseofRTT

Eightmutationsarerecurrentlyfoundindifferentpopulations.ThefirstpartofthemoleculardiagnosisofRTTistheDHPLC-screeningofexons2,3and4ofMECP2.Thisallowstheidentificationofmorethan90%ofalldescribedmutations.Materials

Worksheet:-

LotNo.ofallproducts-

Equipmentidentifiers-

Patient-identifier-

Performingtechnician(s)-

DateofexperimentsMaterialsPCR

-

StandardPCRequipment(Locationxxx)

-

Optimase?DNApolymerase(2.5U/μl)(Locationxxx)

-

Optimase?PCRbufferwithMg2+

(Locationxxx)

-

Primers(Eurogentec)(stock)as250pmol/μl.(appendixA)(Locationxxx)

-

Primerworksolutionscontain2.5pmol/μlofeachprimer(Locationxxx)

-

PuredNTPs(withoutdUTP)(2mM)(Locationxxx)

-

PCRsystemMaterials

DHPLCsystem

-

StandardDHPLCmaterial(forpartnumbersseeappendixCinSOP-O&M)-

WAVE?System3500HT,WAVEMAKER?4.1.44&HSM3.0-2.1build2.

Patientmaterial

-

PatientDNA

-

Positivecontrols

-

Negativecontrols

-

Normalcontrols

UsesofPlasmidControlsasReferenceReagents

noethicalproblems renewableresource CanusesamereferencereagentascontrolforPCR, heteroduplexandmutationdetectionanalysisUniversalreagentswhichcanbeincorporatedinQC proceduresandSOPsAdvantages:

Validationofnewprotocols

Exonspecificwildtypeandmutatedcontrolsforexistingassays

Validationoftransferofprotocolsbetweenmachines/labsUses:Method

Pre-PCR

PCRComposition

PCRConditions

PostPCR

Heteroduplexformation

Agarosegelelectrophoresis

DHPLC

Interpretationoftheresults

ThemutationstandardsatthebeginningandendoftherunareevaluatedAllpositivecontrolsshouldbevisibleattheirspecifictemperatureIfoneofthecontrolsdoesnotfulfillthecriteria,negativeresultsarenotvalidandhavetoberepeated.Positiveresultscanbeprocessedasusual.TheelutionprofilesofaspecificfragmentfromthedifferentpatientsarecomparedwitheachotherandscoredaccordingtothegeneralDHPLCcriteria.Theminimumpeakheightmustbe2mV.Anyparticularobservationshouldbenotedonworksheetsortechnicalreports.Ampliconswithanaberrantelutionpatternarere-analysedbydirectsequencingonanindependentampliconInterpretationoftheresults

Allprematuretruncationmutationsareimmediatelyreportable.Thepathogenicityofthemissensemutationswilldependonthepositionandthetype.Interpretationisthensubjecttogoodpracticeandliteraturereview.MutationsinthetwohighlyconservedMeCP2domains,themethylbindingdomainandthetranscriptionrepressiondomain,arelikelytobecausative.Ifamutationisofunknownsignificance,samplesshouldbeobtainedfromthepatient’sparents.Ifthemutationisfoundtobedenovo,itislikelytobecausative.Ifthemutationispresentinthemother,X-inactivationstudiesneedtobecarriedoutonthemotherofthepatientIfboththemotherandthedaughterhaverandomX-inactivationthemutationisunlikelytobecausative.Reportingprocedures

NEGATIVERESULTINAFEMALENEGATIVERESULTINAMALENORMALPARENTPOSITIVERESULTINAFEMALENEGATIVERESULTINAFEMALE

RettsyndromeiscausedbymutationsintheMECP2gene.Molecularanalysisofthisgenehasbeencarriedoutonpatient******,howevernocausativemutationhasbeenfound.

DHPLCanalysiswasusedtoscreenformutationsintheMECP2gene.Thistechniquehasasensitivityof>95%forthedetectionofpointmutations,microdeletionsandmicroinsertionsbutwillnotdetectgrossdeletionsofentireexons.Only~80%ofRettsyndromepatientshaveadetectablemutationwithintheMECP2gene.NEGATIVERESULTINAMALE

MolecularanalysisoftheMECP2genehasbeencarriedoutonpatient******.Howevernocausativemutationhasbeenfound.

DHPLCanalysiswasusedtoscreenformutationsintheMECP2gene.Thistechniquehasasensitivityof>95%forthedetectionofpointmutations,microdeletionsandmicroinsert

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論